374 related articles for article (PubMed ID: 19088029)
1. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
[TBL] [Abstract][Full Text] [Related]
2. [An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
Kong R; Sun B; Wang SJ; Pan SH; Wang G; Chen H; Xue DB; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(2):128-33. PubMed ID: 20302733
[TBL] [Abstract][Full Text] [Related]
3. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
4. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer.
Kong R; Sun B; Jiang H; Pan S; Chen H; Wang S; Krissansen GW; Sun X
Cancer Lett; 2010 May; 291(1):90-8. PubMed ID: 19880242
[TBL] [Abstract][Full Text] [Related]
7. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Arumugam T; Ramachandran V; Logsdon CD
J Natl Cancer Inst; 2006 Dec; 98(24):1806-18. PubMed ID: 17179482
[TBL] [Abstract][Full Text] [Related]
8. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
[TBL] [Abstract][Full Text] [Related]
10. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
11. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
Wang C; Huang H
Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
14. Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Cao LP; Song JL; Yi XP; Li YX
Oncol Rep; 2013 Apr; 29(4):1659-65. PubMed ID: 23354694
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.
Qanungo S; Uys JD; Manevich Y; Distler AM; Shaner B; Hill EG; Mieyal JJ; Lemasters JJ; Townsend DM; Nieminen AL
Biomed Pharmacother; 2014 Sep; 68(7):855-64. PubMed ID: 25257100
[TBL] [Abstract][Full Text] [Related]
16. Triptolide cooperates with Cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer.
Zhu W; Li J; Wu S; Li S; Le L; Su X; Qiu P; Hu H; Yan G
Pancreas; 2012 Oct; 41(7):1029-38. PubMed ID: 22617708
[TBL] [Abstract][Full Text] [Related]
17. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
18. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
